Entering text into the input field will update the search result below

Repros dips on concern over the validity of its Androxal patent

Aug. 05, 2013 1:47 PM ETRoyalty Pharma plc (RPRX) StockRPRX-OLDBy: David Yelle, SA News Editor
  • Repros Therapeutics (RPRX -2.8%) dips on a negative article in TheStreet.com saying the company is worried about the validity of its Androxal patent.
  • Despite reassurances by RPRX, recent action it's taken to obtain a declaratory judgment affirming its intellectual property rights in a Texas court suggests the company is actually much more worried than it lets on about the risk of it being invalidated.
  • A New York urologist has accused RPRX CEO Joe Podolski of stealing the idea for Androxal from him after a face-to-face meeting in New York City.
  • Podolski denies Fisch's theft charge, but Repros began developing the drug after the meeting between the two men.

Recommended For You

More Trending News

About RPRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RPRX--
Royalty Pharma plc
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.